Gamida Cell Announces the Date of Its Fourth Quarter and Full Year 2022 Financial Results and Webcast
March 20 2023 - 08:00AM
Business Wire
Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working
to turn cells into powerful therapeutics, today announced that the
company will host a conference call and live audio webcast on
Monday, March 27, 2023, at 8:00 a.m. ET to review its fourth
quarter and full year 2022 financial results and provide an update
on the company.
To access the conference call, please register here and be
advised to do so at least 10 minutes prior to joining the call. A
live webcast of the conference call can be accessed in the
“Investors & Media” section of the Gamida Cell website at
www.gamida-cell.com. A replay of the webcast will be available
approximately two hours after the event, for approximately 30
days.
About Gamida Cell
Gamida Cell is a cell therapy pioneer working to turn cells into
powerful therapeutics. The company has a diverse pipeline of
potentially curative cell therapy candidates for patients with
blood cancers and solid tumors. We apply a proprietary expansion
platform leveraging the properties of NAM to cell sources including
umbilical cord blood-derived cells and natural killer (NK) cells to
create allogeneic cell therapy candidates with the potential to
redefine standards of care. These include omidubicel, an advanced
cell therapy candidate for allogeneic hematopoietic stem cell
transplant that, if approved, has the potential to expand access
and improve outcomes for patients with blood cancers, and a line of
enhanced and engineered NK cells targeted at solid tumors and
hematological malignancies. For additional information, please
visit www.gamida-cell.com or follow Gamida Cell on LinkedIn,
Twitter, Facebook or Instagram at @GamidaCellTx.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements as that
term is defined in the Private Securities Litigation Reform Act of
1995, including with respect to timing of the FDA’s review of the
BLA for omidubicel, and the potentially life-saving or curative
therapeutic and commercial potential of Gamida Cell’s product
candidates (including omidubicel). Any statement describing Gamida
Cell’s goals, expectations, financial or other projections,
intentions or beliefs is a forward-looking statement and should be
considered an at-risk statement. Such statements are subject to a
number of risks, uncertainties and assumptions, including those
related to clinical, scientific, regulatory and technical
developments and those inherent in the process of developing and
commercializing product candidates that are safe and effective for
use as human therapeutics. In light of these risks and
uncertainties, and other risks and uncertainties that are described
in the Risk Factors section and other sections of Gamida Cell’s
Quarterly Report on Form 10-Q, filed with the Securities and
Exchange Commission (SEC) on November 14, 2022, and other filings
that Gamida Cell makes with the SEC from time to time (which are
available at http://www.sec.gov), the events and circumstances
discussed in such forward-looking statements may not occur, and
Gamida Cell’s actual results could differ materially and adversely
from those anticipated or implied thereby. Although Gamida Cell’s
forward-looking statements reflect the good faith judgment of its
management, these statements are based only on facts and factors
currently known by Gamida Cell. As a result, you are cautioned not
to rely on these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230319005027/en/
Investor Contact: Courtney Turiano Stern Investor
Relations, Inc. Courtney.Turiano@sternir.com 1-212-362-1200
Media Contact: Dan Boyle Orangefiery dan@orangefiery.com
1-818-209-1692
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From May 2023 to Jun 2023
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Jun 2022 to Jun 2023